Chicago Atlantic BDC Q2: Income Soars After Loan Acquisition; NAV Flat, Cannabis Risk

Chicago Atlantic BDC, Inc. (NASDAQ: SSIC) - Quick read on what's happening inside the company

Snapshot / headline
- The company's June 30, 2025 10‑Q shows a materially larger operating platform after the October 1, 2024 Loan Portfolio Acquisition. Investment income and net investment income have surged year‑over‑year; NAV per share is essentially flat but portfolio fair value expanded to ~ $307.5M.

Key facts & figures (as reported)
- Total assets: $331,750,419
- Investments at fair value: $307,499,004
- Cash & cash equivalents: $13,829,354 (down from $23.9M at 12/31/24)
- Total liabilities: $29,906,856
- Total net assets: $301,843,563
- NAV per share: $13.23 (6/30/25) vs $13.20 (12/31/24)
- Shares outstanding: 22,820,408
- Total investment income (Q2 2025): $13,080,038 vs $3,081,333 (Q2 2024)
- Interest income (Q2 2025): $11,906,066
- Net investment income (Q2 2025): $7,664,607 vs $1,525,633 (Q2 2024)
- Net increase in net assets (Q2 2025): $8,584,265; YTD (six months) increase: $16,198,622
- Distributions declared: $0.34 per share (each quarter); two distributions in H1 2025 totaled ~$15.52M paid

Portfolio composition & concentration
- Total investments: $307.5M (Level‑3 fair values; valuation judgment significant)
- Debt-heavy: ~99.6% of investments are debt instruments (first lien and senior secured notes). First‑lien senior secured loans constitute ~87% of portfolio by fair value.
- Cannabis concentration: ~78.5% of portfolio fair value in cannabis-related investments (portfolio strategy remains concentrated).
- Rate profile (principal basis): Fixed-rate ~23.8%; Floating-rate (SOFR) ~8.3%; Floating-rate (Prime) ~67.9%.
- Top-name concentration: 3 portfolio companies = 39.5% of portfolio fair value; largest single position = 16.8%.

Leverage & liquidity
- Revolving credit facility: up to $100M; $5.0M outstanding at 6/30/25; $95M available
- Loans pledged as borrowing base collateral: ~$233.9M (principal) pledged
- Deferred financing costs on balance sheet: $830,531
- Cash decreased from $23.9M (12/31/24) to $13.8M (6/30/25); operating cash used H1 2025 = $(5.31M)

Positive aspects of the income statement / results
- Large revenue growth: total investment income jumped to $13.08M (Q2) and $25.00M (YTD) driven by larger loan portfolio and higher interest income.
- Net investment income increased materially: Q2 2025 NII $7.66M vs $1.53M a year earlier - shows immediate earnings benefit from portfolio scale.
- NAV stability/edge: NAV per share edged up to $13.23 from $13.20 despite paying sizable cash distributions (two $0.34 quarters in H1).
- No loans on non‑accrual as of 6/30/25 - portfolio performance (on accrual basis) appears acceptable for now.

Negative aspects / red flags on the income statement and balance sheet
- Expense growth and incentive fees: Total expenses increased sharply (six months ended 6/30/25: $11.46M vs $4.40M prior year). Income‑based incentive fees alone were $3.88M YTD - a meaningful drag on net returns and highly linked to adviser economics.
- Heavy reliance on adviser waivers and expense cap: Company recorded expense waivers (Expense Limitation Agreement) of $1.11M YTD and other waivers - recurring reliance could mask underlying cost pressure.
- High valuation uncertainty: 100% of investments are Level‑3 fair values; fair‑value judgments (discount rates, DCF inputs) are subjective - a risk for future volatility and future NAV swings.
- Concentration in one sector: ~78.5% in cannabis - sector risk, regulatory uncertainty, federal illegality in the U.S., and potential collateral enforceability issues raise downside risk.
- Market price disconnect: market price per share (period end) was $10.35 vs NAV $13.23 - ~22% discount, signaling investor concern or illiquidity.
- Liquidity tightening / cash burn: cash fell by ~$10.1M in H1 2025; while a $100M revolver exists, $233.9M in loans are pledged and $5M is drawn - leverage exposure and potential covenant/foreclosure risk if stress emerges.

Other operational and financial risks
- Valuation sensitivity: management reports discount rate ranges with weighted‑average discount for loans ~13.3% - increases here materially reduce fair value.
- Concentrated credit risk: few large positions dominate NAV; a default or large loss at a top position would hit NAV hard.
- Related‑party fees and arrangements: material fees to Adviser and affiliates, co‑investments with affiliates, and administrative relationships are significant and increase governance/watchlist items.
- Non‑qualifying assets and regulatory constraints: non‑qualifying assets exist (though modest as of 6/30/25 ~3.38% of total assets), and BDC/RIC rules drive distribution requirements and tax mechanics.

Notable subsequent event
- On July 31, 2025 the company reported a principal repayment of ~ $38.7M (full repayment of loan to STIIIZY Inc.) - a material post‑period repayment that will affect liquidity and portfolio composition.

Bottom line (straightforward)
- The company has successfully scaled earnings and investment income after acquiring a big loan portfolio - NII and interest income improved sharply. But the story is high risk/high reward: the portfolio is concentrated in cannabis, heavily valued at Level‑3 inputs, and the company pays meaningful advisor incentive and management fees. NAV is stable (small uptick) but shares trade at a material discount. Monitor: portfolio credit performance (non‑accruals), adviser fee trends, valuation assumptions (discount rates/volatility), and the company's use of its revolver and remaining cash.

If you want, I can convert this into a short investor checklist, a one‑page risk/return scorecard, or pull a timeline of expected maturities and distribution coverage metrics.